Back to top

Ocugen granted RMAT designation for OCU410

Ocugen (OCGN) announced that the FDA has granted RMAT designation to Ocugen’s investigational product OCU410 for the treatment of geographic atroph...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Ocugen, Inc. (OCGN)